The global market for Biological Drugs was estimated at US$345.3 Billion in 2023 and is projected to reach US$634.4 Billion by 2030, growing at a CAGR of 9.1% from 2023 to 2030. This comprehensive ...

Hospitals and generic drugmakers have join big pharma lobbyists who have said such trade barriers will cause shortages of ...

Poland’s poor availability of biological and biosimilar medicines is under the microscope, with policymakers pushing for new accessibility measures to benefit patients in need of advanced therapies.

With patents on originator biologic medicines beginning to expire in the United States, there’s a growing opportunity for biosimilars to enter the market as alternative therapeutic options at ...

Biologics - advanced and complex medicines derived from living organisms such as insulin or monoclonal antibodies - offer more targeted treatments than traditional small molecule drugs ...

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...

A biomaterial that can mimic certain behaviors within biological tissues could advance regenerative medicine, disease ...

A biological medicine is any medicinal product made by or derived from a biological (natural) source, for example, an animal cell or microorganism. The first biological medicine to be approved for use ...

When considering manufacturing and the growth of drug formulation, it is evident that there has been change and many new advancements introduced to make processes more efficient.

including parity in its treatment of drugs that are primarily pills and capsules compared with complex biologic medicines. Under the IRA, oral drugs are eligible for Medicare price negotiation ...